Amgen falls short in Epogen patent appeal but Pfizer stumble delays competition

Fierce Pharma ------ With a federal appeals decision handed down this week, Amgen has come up short in a legal attempt to defend blockbuster anemia med Epogen from a Pfizer biosim. However, the company’s loss in appeals doesn’t mean its drug will face cheap competition right away. An appeals panel ruled that it doesn’t have jurisdiction over a lower court’s order denying Amgen’s request for more info about Pfizer’s product. The dispute stems from whether Pfizer met requirements of the Biologics Price Competition and Innovation Act (BPCIA) as it seeks to bring another biosim to market. To learn more click on the picture below to read the article.